During the Fifth Edition of Africa Health ExCon 2026 EDA Signs Memorandum of Understanding with Algeria’s National Agency of Pharmaceutical Products to Strengthen Regulatory Cooperation and Exchange Expertise

Al-Ghamrawy: Arab and African Regulatory Partnerships Are a Fundamental Pillar for Strengthening Pharmaceutical Security and Enhancing Regulatory Integration in Line with the Latest International Standards

Dali: Cooperation with the Egyptian Drug Authority Opens New Horizons for Regulatory Integration and Supports the Quality and Safety of Medical Products Across Africa

Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), signed a Memorandum of Understanding (MoU) with Dr. Cherif Dali, Director General of the National Agency of Pharmaceutical Products of the People's Democratic Republic of Algeria, to strengthen cooperation in the fields of pharmaceutical products and medical devices, supporting the exchange of expertise and the development of regulatory and oversight systems in both countries.

The signing ceremony was witnessed by H.E. Prime Minister Dr. Mostafa Madbouly, reaffirming the political leadership’s support for regional and continental cooperation in the healthcare sector and highlighting the importance of regulatory partnerships in strengthening pharmaceutical security and ensuring the stability of supply chains.

The Memorandum of Understanding aims to enhance technical and regulatory cooperation in the fields of pharmaceutical products and medical devices, as well as the exchange of information, expertise, and regulatory best practices. These efforts will contribute to strengthening the efficiency of regulatory and oversight systems while enhancing the quality, safety, and efficacy of medical products available in the market.

The memorandum also includes cooperation in the registration of pharmaceutical products and medical devices, inspection and regulatory oversight, pharmacovigilance, and the exchange of technical and scientific expertise. In addition, it supports capacity-building programs and the training of specialized personnel in line with the latest international standards and best practices.

Dr. Ali El-Ghamrawy emphasized that the signing of the memorandum reflects the deep-rooted fraternal and historical ties between the Arab Republic of Egypt and the People's Democratic Republic of Algeria. He noted that it also demonstrates the Egyptian Drug Authority’s commitment to strengthening cooperation with Arab and African regulatory authorities and expanding strategic partnerships aimed at advancing pharmaceutical and regulatory systems, thereby promoting regulatory integration and supporting pharmaceutical security across the African continent.

He further stated that the Authority continues its efforts to reinforce Egypt’s position as a leading regional hub in the pharmaceutical sector through the establishment of effective partnerships that facilitate the exchange of expertise, harmonization of regulatory approaches, and broader access to safe, effective, and high-quality medical products.

For his part, Dr. Cherif Dali highlighted the importance of the Memorandum of Understanding in opening new avenues for cooperation between the two sides and maximizing the benefits of shared expertise in regulatory and oversight fields. He noted that such collaboration supports the development of pharmaceutical systems and contributes to ensuring the availability of safe and effective pharmaceutical products and medical devices that meet the highest quality standards.

The signing of the memorandum comes within the framework of the Egyptian Drug Authority’s strategy to strengthen regional and continental cooperation with counterpart regulatory authorities and promote the exchange of expertise and regulatory best practices. These efforts contribute to enhancing the efficiency of regulatory systems, improving the quality, safety, and efficacy of pharmaceutical products and medical devices, and reinforcing Egypt’s role as an active regional partner in supporting pharmaceutical security and the development of pharmaceutical industries across the Arab and African regions.